SUMMARY Correlations were made between weight change (as an index of volume loss) and blood pressure (BP) reduction before and after hydrochlorothiazide treatment A total of 343 patients with mild to moderate hypertension (95-114 mm Hg) received hydrochlorothiazkle alone. The diuretk was titrated from 50 to 100 to 200 mg daily as needed until the diastolic BP fell below 90 mm Hg (goal BP) or side effects supervened. Of the 305 patients who completed the 10-week titration period, 65% attained goal BP. The effective dose of hydrochlorothiazide hi 52% of these responders was 50 ing/day, and this was associated with weight loss averaging 1.58 kg. An additional 29% achieved goal BP with a similar degree of weight loss, but they required double the dose, or 100 ing/day. The remaining 19% of responders required significantly greater weight reductions averaging 3.14 kg to achieve goal BP, which necessitated hydrochlorothiazide, 200 mg/day. More blacks than whites attained goal BP despite similar degrees of weight loss in the two races. Plasma renin activity was initially higher in whites than in blacks and rose significantly more in blacks and whites requiring the greatest volume losses and the highest dose of hydrochlorothiazide to attain goal BP. Nonresponders had less weight loss than responders. Thus, diuretic dose requirements vary hi different patients and are related either to different volume losses hi response to a given dose or to different degrees of BP reduction hi response to the same volume loss. 
T HERE is a close association between volume reduction and the antihypertensive response to diuretics. It has long been known that diuretics cause a moderate reduction in extracellular fluid volume and plasma volume of approximately 10 to 15%. 1 2 This volume reduction, although moderate, appears to play an important role in the fall of blood pressure (BP) following diuretics. The volume depletion is reflected in a weight loss of about 1.4 to 2.7 kg. 1 ' 3 The loss of volume occurs primarily over the first 3 or 4 days of continuous treatment, after which no further volume depletion occurs. 1 A new equilibrium is established, characterized by moderately reduced extracellular and plasma volumes. If the diuretic is discontinued, however, the extracellular volume is quickly restored.
There is considerable interindividual variation in the degree of antihypertensive response to a given dose of thiazide diuretic. 4 - 5 However, it is not clear whether the antihypertensive response is related to the amount of volume depletion to a given dose or to variation of the degree of antihypertensive response to the same volume loss. Another controversial issue concerning the thiazide diuretics involves the dose-response relationship. While several studies 6 -8 found that the dose-response curve to hydrochlorothiazide (HCTZ) is flat beginning with a dose as small as 12.5 mg/day, other data indicate that the curve continues to rise with further dosage increases to considerably higher levels without becoming flat. 4 -9 -10 In the Veterans Administration Cooperative Study on HCTZ versus propranolol each drug was given as monotherapy, thus providing an opportunity for studying the dose-volume-BP relationships associated with HCTZ alone in a large number of patients. 4 - 5 Changes in body weight before and after the drug were used as an index of volume change.
Patients and Methods
The design of the Veterans Administration Cooperative Study on propranolol versus HCTZ as monotherapy has been described in detail elsewhere 4 and will be only briefly summarized here. The study included 906 asymptomatic male veteran patients with pretreatment diastolic BP between 95 and 114 mm Hg. After a placebo run-in period of 8 weeks, 683 of the patients who met the criteria for entry were randomly assigned, double-blind, to receive either HCTZ or propranolol. Of this number 343 received HCTZ.
Dosages of both drugs were titrated over a period of 10 weeks. Of the patients who were randomly assigned to HCTZ, doses were titrated as needed to achieve a diastolic BP below 90 mm Hg (goal BP). The three dosages of HCTZ were 25, 50, and 100 mg given twice daily, that is, 50, 100, and 200 mg/day. Compliance was monitored by pill counts.
BP at each visit was recorded as follows: The patient rested undisturbed in the supine position for 10 minutes, after which his BP was recorded three times each in the supine, sitting, and erect positions. Only the average of the three sitting readings are reported here.
In the present analysis, comparisons were made between the last visit of the pretreatment baseline period and the end of the 10-week titration period. Body weight was measured, using a beam balance, after overnight fasting with the patient clothed in shirt-sleeves. The principal variables were body weight, BP, dose of HCTZ, plasma renin activity (PRA), and race. The change in body weight before and after diuretic treatment was used as an index of change in extracellular fluid volume. In previous studies reductions in weight after HCTZ treatment have been shown to correlate with losses of extracellular fluid volume. 1 -3 The unpaired Student's t test, chi square test, and analysis of variance (ANOVA) were used to assess statistically significant differences (defined as p < 0.05) between groups of data.
PRA and 24-hour urine excretion of sodium and potassium also were determined at the end of the pretreatment placebo phase and at the end of the 10-week dose-titration period. PRA was determined by a method described in a previous communication. 11 Urine sodium and potassium concentrations were determined from 24-hour urine collections by flame photometry using a lithium internal standard.
Compliance rates were calculated using the pill counts taken at the last visit of the titration phase. The four groups analyzed comprised the three doseresponse groups plus the nonresponders. The results were tested first with ANOVA to determine overall rates of difference among groups. Duncan's multiple range test was then used to determine which groups were significantly different. The tests were done for blacks and whites separately and for both groups combined.
Results
Approximately half of the HCTZ responders (103 or 52%) achieved the therapeutic goal of a diastolic BP below 90 mm Hg with the lowest prescribed dose or 50 mg of HCTZ per day. The weight loss of the patients achieving the BP goal averaged 1.58 kg (Table 1 ). This loss was greater than the 1.21-kg weight loss of the 202 patients who did not achieve goal BP at the same dose of HCTZ (p = 0.094). The difference in BP reduction was considerable ( Table  2 ). The fall in diastolic BP among the responders to the 50 mg/day dose averaged -15.1 mm Hg, as compared with -5.6 mm Hg among the nonresponders to this dose of HCTZ (p < 0.001).
Fifty-eight patients (29%) of responders to HCTZ required a daily dose of 100 mg of HCTZ to achieve goal BP. Their average fall in diastolic BP was -16.3 ± 6.1 (SD) mm Hg at the 100-mg dose whereas at the 50-mg dose it had averaged -7.5 mm Hg, which was significantly less than the 50-mg responders (p < 0.001; see Table 2 ). At a HCTZ dose of 100 mg/day, responders lost an average of 1.63 kg (see Table 1 ), which was similar to the weight loss experienced by the responders to the 50 mg/day dose. When they received HCTZ, 50 mg/ day, the average weight loss of the 100-mg responders was less than that of the responders to the 50-mg dose (see Table 1 ) although the difference was not significant (p = 0.28).
Thirty-eight (19%) of the responders required HCTZ, 200 mg/day, to achieve the goal BP. At the 200-mg dose these patients exhibited significantly greater weight loss averaging 3.14 kg (p < 0.001) than the responders to the lower doses. At this level of weight loss, however, diastolic BP fell 14.4 mm Hg. This was similar to the diastolic BP change in the responders to the 50-and 100-mg doses, which averaged -15.5 mm Hg. At HCTZ doses of 50 and 100 mg/day the BP of the 200-mg responders was not controlled despite their having a weight loss equal to or greater than that of low dose responders. Their average weight loss was 1.64 kg at the 50-mg dose and 2.14 kg at the 100-mg dose, which was slightly greater than that of the responders to these lower doses. In short, attainment of the goal BP required a greater volume loss than was needed by the other responders.
There were 106 patients who failed to achieve goal BP at any dose including HCTZ, 200 mg/day. They consistently had less average weight loss at each dose level of diuretic than did the responders. For example, their weight loss at 50, 100, and 200 mg of HCTZ daily averaged only -1.05, -1.23, and -1.68 kg respectively as compared with -1.58, -1.64, and -3.14 kg in the responders (see Table 1 ).
As judged by the pill counts, the patients who failed to respond to any dose were significantly less compliant than responders to the 50 mg/day dosage (p < 0.05; Table 3 ). Nevertheless, compliance was still comparatively good among the nonresponders as judged as they averaged taking 81.5% of their prescribed medication. The patients receiving HCTZ, 200 mg/day, also were required to take two tablets twice daily, whereas the patients responding to the lower doses took only one tablet twice daily.
To estimate whether the differences in compliance rates could have had a determining influence on some of the results, these rates were used to estimate the actual average daily dose in milligrams as corrected for pill counts. The results are given in Table 3 . This analysis shows that the differing compliance rates probably were not enough to change significantly the amount of drug ingested and, therefore, probably did not account for the observed differences in response. However, since pill counting is not an entirely reliable technique, the compliance data cited must be interpreted with caution, especially regarding the nonresponders to all doses of HCTZ. Table 2 gives the BP results for blacks and whites separately. As was noted in previous communications, 4 -5 the blacks were more responsive to HCTZ than were the whites. Seventy-five (45%) of the black achieved the BP goal with the smallest dose of HCTZ, 50 mg/day, as compared with only 20% whites {p < 0.001). Also, only 27% of blacks were nonresponders to any dose, as compared with 44% of whites. There was a consistently greater fall of BP in blacks (see Table 2 ). However, this decrease was not accompanied by a greater weight loss than that seen in whites (see Table 1 ). There was no trend toward greater weight loss among blacks; except for minor variations, the weight change in the two racial groups was essentially similar. Table 4 and Figures 1 and 2 indicate PRA in relation to HCTZ effective dosage during the pretreatment baseline period and the changes in PRA after the 10-week titration period with HCTZ. At baseline, for black and white patients combined, mean PRA levels for each group ranged between 0.77 and 1.20 ng angiotensin I (Ang I)/ml/hr (see Table 4 ) for the different dose-response groups (see Table 4 and Figure 1) .
Racial Differences

PRA in Relation to Hydrochlorothiazide Responsiveness
White patients tended to show higher levels of PRA than did blacks at baseline. For the total patients (blacks and whites combined) the baseline PRA level among the 200-mg HCTZ responders averaged 41% higher than the mean PRA of the responders to the two lower doses of HCTZ. This difference was not statistically significant, however, possibly due to the sample sizes, particularly of the 200-mg responders. At baseline the only significant difference with respect to dosage requirements was in blacks requiring the 200-mg dose of HCTZ, who exhibited significantly higher PRA levels than did black patients responding to the lower doses of HCTZ {p < 0.05, by Duncan's test). This pattern was not found in the white patients, as the highest PRA value occurred in the responders to the 50-mg dose of HCTZ, although this difference was not significant (see Table 4 and Figure 1 ).
Following the 10-week titration period with HCTZ, PRA rose in all groups (see Table 4 and Figure 2 ). For black and white patients combined, PRA increased by 3.21 ng Ang I/ml/hr for the 50-mg HCTZ responders and by 7.91 ng Ang I/ml/hr for those requiring HCTZ, 200 mg/day, for the various groups. The difference in PRA changes between the patients responding to the two lowest doses was significantly less than that in the 200-mg responders and the nonresponders. Similar group differences in PRA increase between the two lowest and the two highest doses of HCTZ were seen in black {p = 0.0013) and white patients (p = 0.02).
Sodium and Potassium Excretion
Before treatment the excretion of sodium averaged between 175 and 194 mEq/24 hr for the various HCTZ dosage groups and was not significantly different after 10 weeks in blacks and whites. Baseline potassium excretion varied between 50 and 67 mEq/24 hr among the different dose responders. The 24-hour excretions after 10 weeks of diuretic treatment were essentially the same. As was the case with sodium, there was no correlation between potassium excretion and responsiveness to HCTZ. Discussion These data support other studies that BP reduction is associated with volume depletion.
1 -2 The present results suggest that there are three main types of responders, as characterized by the dose of diuretic and weight (volume) change associated with attaining goal BP. The first and largest group responded to the smallest of the three doses of HCTZ, which was 50 mg/day. In this group diastolic BP below 90 mm Hg was achieved with only a moderate volume loss, as reflected by weight changes. This group of patients comprised 52% of the diuretic responders; the remainder required higher doses of HCTZ. Because lower doses were not tested, it is not possible to determine how many of these patients would have responded to daily doses below 50 mg.
The second group, comprising 29% of the responders, achieved goal BP at a similar degree of weight loss, but they required a higher dose of HCTZ to attain it. Therefore, although both groups achieved goal BP with essentially the same degree of volume loss, the second group required a larger dose of diuretic to obtain as great a volume loss as the 50-mg responders.
The third and least frequent type of responder required much greater weight (volume) loss, averaging 3.4 kg, to achieve goal BP, which was approximately double the average weight loss of 1.59 and 1.64 kg among the 50 and 100 mg/day responders, respectively. This goal was attained only with the highest dose of HCTZ, 200 mg/day. The lower doses of diuretics in the 200 mg/day responders caused as great, or greater, weight loss as the groups whose BP responded. These results indicate that the patients requiring the highest dose of HCTZ needed greater than average volume loss to achieve goal BP. This group also exhibited the highest PRA levels among the responders (see Table 4 and Figures 1 and 2 ). Thus, with respect to dose-volume changes, the three kinds of response may be characterized as follows: Group 1, whose BP responded to a small dose of diuretic associated with an average volume loss; Group 2, or dose-resistant patients, who required a higher dose of diuretic to achieve a volume loss similar to that in Group 1 but who thereafter also responded with a BP reduction similar to that in Group 1; and Group 3, or volumeresistant patients, who required significantly greater volume loss to attain goal BP, which could be achieved only with the highest dose of HCTZ. Approximately 50% of the responders achieved goal BP with the lowest dose of HCTZ, 50 mg/day, 30% required 100 mg, and 20% needed the highest dose of 200 mg/day. Approximately 35% of the randomized patients failed to achieve goal BP with any of the doses of diuretic. They also had lesser degrees of weight loss. At any given dose of HCTZ their loss of body weight was less than that of the responders. The reason for the difference is not apparent. The most obvious explanation is that the resistant patients were poor compilers.
Poor compliance, however, did not appear to be the entire explanation for the lack of response of the resistant patients. When the average daily intake of HCTZ was estimated using pill counts, the difference between responders and nonresponders was not great, suggesting that poor compliance probably was not the reason for the failure of the nonresponders to reach goal BP. Further evidence of an unimportant difference in compliance is suggested by the fact that serum potassium levels decreased equally at the 200 mg/day dose in both the responders and the nonresponders. In addition, PRA levels rose nearly as high as those in the 200-mg HCTZ responders. The failure of these patients to achieve an antihypertensive response, therefore, could be due to a diminished diuretic response rather than to poor compliance. A diminished diuresis would result in inadequate volume depletion as was demonstrated by the lesser degree of weight loss.
As expected, PRA increased markedly in all dosage groups following HCTZ. It is well known that PRA increases with reduction in volume. 12 The studies also extend prior observations on the greater antihypertensive responsiveness to thiazide diuretics of blacks as compared with whites. 4 -5 Doses of diuretics required to attain effective weight loss varied in different patients, but, in general, more blacks than whites were responsive to smaller doses of diuretic. Since there was no essential difference in weight loss between blacks and whites, the greater antihypertensive response must have been due to other unknown factors that caused blacks to exhibit greater antihypertensive responsiveness despite essentially the same degree of volume depletion.
Except for the nonresponders, PRA rose higher at each dose level of HCTZ in whites than in blacks.
Since PRA increases angiotensin and aldosterone levels, the greater increase of PRA in whites may raise BP and so increase the resistance to the antihypertensive effects of the diuretics. The greater levels of PRA and, therefore, angiotensin may cause more vasoconstriction, thereby competing with the antihypertensive effect of the diuretic. Similarly, the lower levels of PRA, which usually occurred in blacks as compared with whites during the pretreatment period as well as during treatment with HCTZ, may account at least in part for the increased responsiveness of blacks to the antihypertensive effects of diuretics. 4 PRA levels correlated more with dosage and the resultant degree of volume loss than with BP changes. Thus, the three dosage groups reached similar levels of BP because of the nature of the titration procedure, which increased dosage until the diastolic BP reached goal levels of 90 mm Hg or less or to a top level of 200 mg/day. Their baseline pressures also were not significantly different, as can be seen in Table 1 . The decrements in BP in the three dosage groups were similar, averaging 15.1 mm Hg for the 50 mg/day dose and 14.4 mm Hg for the 200 mg/day dose, an insignificant difference. On the other hand, total extracellular volume, as estimated from changes in body weight, decreased 3.14 kg with the 200 mg dose, which was much more than the losses averaging 1.59 and 1.64 for the two smaller doses of 50 and 100 mg/day (see Table 1 ). These weight (volume) changes rather than the BP change correlated with the alterations in PRA levels after HCTZ treatment. The elevations above pretreatment levels, while present with all doses, were significantly less in the 50-and 100-mg HCTZ dose-response groups than in the 200-mg patients.
These observations are consistent with the wellknown role of the renin-angiotensin-aldosterone system in the regulation of extracellular fluid volume. 12 Decreases in volume from whatever cause activate the renin system, which in turn influences the kidney to conserve salt and water. The marked rise in PRA that we observed following HCTZ-induced volume loss, as was seen particularly with the two highest doses of HCTZ, is consistent with this response.
The 24-hour excretion of sodium and potassium were similar at baseline and 10 weeks after beginning treatment. These results are the same as those reported by Wilson and Freis, 13 which indicated that the net electrolyte losses from body stores occur in the first 48 to 72 hours after beginning the diuretic therapy. Excretion subsequently comes into balance with intake, and no further net loss of body electrolytes occurs.
There was no evidence of a flat dose-response curve within the present range of dosage, since one fifth of the responders required a high HCTZ dose of 200 mg/day. These results are in contrast to other reports indicating that the dose-response curve reaches a plateau with small doses of HCTZ, such VOL 12, No. 3, SEPTEMBER 1988 as 12.5 or 25 mg/day. 6 -8 The discrepancy may be due at least in part to the fact that in the other studies the diuretic was usually given in combination with a Step 2 drug. However, our group performed similar Step 2 studies 13 and found that daily doses of 12.5 mg of HCTZ were inactive as compared with placebo when given in combination with nadolol. A dose of 25 mg/day lowered systolic but not diastolic BP, while only the highest dose, which was 50 mg/day, lowered both systolic and diastolic BP. Therefore, our earlier studies also failed to find evidence of a flat dose-response curve with smaller doses of HCTZ even when combined with a Step 2 drug. The present findings again indicate that the eflFective dose of HCTZ varies over a wide range in different patients. In a smaller group of patients greater volume losses are needed to attain adequate BP control. Such patients require doses that are above the usually accepted therapeutic range.
